中科生物(01237.HK)上半年扭虧為盈至420萬元
格隆匯8月30日丨中科生物(01237.HK)公佈,截至2021年6月30日止6個月,集團的收入較去年同期下跌11.9%至人民幣2.52億元。自2020年下半年起,集團把其營銷重心投放於澳大利西亞,以應對美國就從中國進口的木線條及木製品所急劇加徵的關税。美國加徵關税導致集團於2020年整年錄得嚴峻的負毛利率,而成功把主要市場轉移至澳大利西亞,集團得以達到14.6%毛利率,並在期內扭虧為盈,錄得溢利人民幣420萬元(2020年上半年:人民幣28000萬元虧損)。
集團的核心業務分部包括生產及銷售木製品;零售;及生產及銷售再生能源產品。期內,該等三個業務分部收益分別約人民幣2.49億元、無及人民幣300萬元,佔總收益98.8%、0.0%及1.2%。
生產及銷售木製品仍然是集團的最大業務分部,佔集團收益的98.8%。有關業務分部產生的收益減少11.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.